Bioxytran Announces Preprint of Shingles Case Study
First Medicinal chemistry of an antiviral drug made of sugars BOSTON, MASSACHUSETTS, Feb. 21, 2024 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT), (the Company), a clinical stage biotechnology...
Thursday, October 5, 2023 10:15 am 10:45 am ESTSmall Pharma Strategy BOSTON, MASSACHUSETTS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the œCompany), a clinical stage...
BOSTON, MASSACHUSETTS, Sept. 14, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the œCompany), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
First Antiviral Drug in Glycovirology BOSTON, MASSACHUSETTS, Aug. 24, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the œCompany), a clinical stage biotechnology company developing oral...
BOSTON, MASSACHUSETTS, Aug. 08, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the œCompany), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
BOSTON, MASSACHUSETTS, July 31, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the “Company”), a clinical stage biotechnology company developing oral drugs to treat COVID-19 and other viral...
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo (p=.001)Complete elimination of most symptoms by day 7Galectin antagonist acts as an entry inhibitor for use in...
- Funding in place to meet next regulatory milestone BOSTON, MASSACHUSETTS, June 12, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (BIXT), (the œCompany), a clinical stage biotechnology company...
Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed Article BOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)...